Abstract: The presently described catheter is an improved multi-function hypospadias catheter adapted to be urethrally inserted and secured within a patient's bladder using an attached internal crescent shaped retention balloon. The inverted crescent configuration of the balloon reduces the contact surface area between the balloon and a patient's bladder wall to reduce bladder spasms. The catheter is removed from the patient (when needed) via deflation of the crescent shaped balloon, which deflates completely so as to not contact a patient's urethra during insertion and removal of the catheter. The catheter includes a double lumen with a one-way flow valve. One lumen provides a passageway to drain urine from a patient's bladder. The second lumen provides a passageway to inflate and deflate the crescent shaped retention balloon.

Abstract: A pyelo-ureteral stent is provided that combines the benefits of a stent having a lumen with the benefits of a lumen-less stent. In one example, the stent may be implanted in a patient for use during and after a pyeloplasty procedure. The provided stent includes a flexible tube having two separate lumens. Each lumen terminates prior to the stent's closed distal end, which enables a lumen-less ureteric limb at the stent's closed distal end. The lumen-less ureteric limb may have a smaller diameter than the rest of the stent, and may be positioned in a patient's ureter to bridge the pyeloplasty repair, thereby providing the benefits of a lumen-less stent. The flexible tube may be formed with at least one perforated coil for the drainage of urine and/or blood. The stent may be removed from the patient without the use of a cystoscopic procedure.

Abstract: The systems and methods relate to a self-serve diagnostic experience that enables users to help themselves when issues or problems emerge with a customer workload. The systems and methods provide an interactive interface that guides users through a troubleshooting journey. Users may enter a problem with a customer workload using the interactive interface and may receive one or more insights automatically generated by one or more detectors based on an analysis of the backend telemetry data for the customer workload. The insights may provide contextual information about the issues and recommendations for steps to fix the issues. The interactive interface may also provide a visual overview of a plurality of resources, the resource dependencies, and the resource health for the plurality of resources. The systems and methods may also guide users in building one or more detectors for troubleshooting the one or more issues.

Abstract: The presently described catheter is an improved multi-function hypospadias catheter adapted to be urethrally inserted and secured within a patient's bladder using an attached internal crescent shaped retention balloon. The inverted crescent configuration of the balloon reduces the contact surface area between the balloon and a patient's bladder wall to reduce bladder spasms. The catheter is removed from the patient (when needed) via deflation of the crescent shaped balloon, which deflates completely so as to not contact a patient's urethra during insertion and removal of the catheter. The catheter includes a double lumen with a one-way flow valve. One lumen provides a passageway to drain urine from a patient's bladder. The second lumen provides a passageway to inflate and deflate the crescent shaped retention balloon.

Abstract: Compounds and methods of making them having the following formula are described which bind to selectin receptors and thus modulate the course of inflammation, cancer and related diseases by modulating cell-cell adhesion events: ##STR1## wherein each R.sup.1 is independently H or lower alkyl (1-4C); R.sup.2 is H, OH or lower alkyl (1-4C), or a lipophilic group such as a higher alkyl group (5-15C), alkylaryl or one or more additional saccharide residues;R.sup.3 is a negatively charged moiety including SO.sub.4.sup.2-, PO.sub.4.sup.2-, or related group;Y is H or lower alkyl (1-4C); andX is H or --CHR.sup.4 (CHOR.sup.1).sub.2 CHR.sup.5 OR.sup.1 wherein R.sup.4 and R.sup.5 are each independently H, lower alkyl (1-4C), or taken together result in a five- or six-membered ring optionally containing a heteroatom selected from the group consisting of O, S, and NR.sup.1 ;said five- or six-membered ring optionally substituted with one substituent selected from the group consisting of R.sup.1, CH.sub.2 OR.sup.1, OR.sup.

Abstract: Compounds and methods of making them having the following formula are described which bind to selectin receptors and thus modulate the course of inflammation, cancer and related diseases by modulating cell-cell adhesion events: ##STR1## wherein each R.sup.1 is independently H or lower alkyl (1-4C); R.sup.2 is H, OH or lower alkyl (1-4C), or a lipophilic group such as a higher alkyl group (5-15C), alkylaryl or one or more additional saccharide residues;R.sup.3 is a negatively charged moiety including SO.sub.4.sup.2-, PO.sub.4.sup.2-, or related group;Y is H or lower alkyl (1-4C); andX is H or --CHR.sub.4 (CHOR.sup.1).sub.2 CHR.sup.5 OR.sup.1 wherein R.sup.4 and R.sup.5 are each independently H, lower alkyl (1-4C), or taken together result in a five- or six-membered ring optionally containing a heteroatom selected from the group consisting of O, S, and NR.sup.1 ;the five- or six-membered ring optionally substituted with one substituent selected from the group consisting of R.sup.1, CH.sub.2 OR.sup.1, OR.sup.

Abstract: Simple lactose or lactosamine related compounds which behave as ligands for the ELAM-1 and related receptors are described. These compounds are useful in the treatment of conditions characterized by excess inflammation. These compounds are of the formula ##STR1## wherein each R.sup.1 is independently H or lower alkyl (1-4C); R.sup.2 is H, lower alkyl (1-4C), alkylaryl or one or more additional saccharide residues;R.sup.3 and R.sup.4 are each independently H, alkyl(1-6C), aryl or R.sup.3 and R.sup.4, taken together, form a five- or six-membered ring optionally containing a heteroatom selected from the group consisting of O, S, and NR.sup.1 ;wherein said five- or six-membered ring may further be substituted by one or more substituents selected from the group consisting of (CHOR.sup.1).sub.m H wherein m is 1-4, OR.sup.1, OOCR.sup.1, NR.sup.1.sub.2, NHCOR.sup.1, and SR.sup.1 ;Y is H, OR.sup.1, OOCR.sup.1, NR.sup.1.sub.2, NCOR.sup.1 or SR.sup.1 ; andX is --CHR.sup.5 (CHOR.sup.1).sub.2 CHR.sup.6 OR.sup.1 wherein R.

Abstract: Glyco-amino acids or glycopeptides that have three-dimensionally stable configuration for the presentation of functional groups, fucose, or an analogue or derivative thereof, covalently linked to an amino acid or peptide with a free carboxylic acid group, that facilitate binding between those groups and receptors on selectins, represented by the general structural formula I.

Abstract: The compounds are of the formula ##STR1## wherein each R.sup.1 is independently H or lower alkyl (1-4C); R.sup.2 is H, lower alkyl (1-4C), alkylaryl or one or more additional saccharide residues; R.sup.3 and R.sup.4 are independently H, alkyl (1-6C), aryl or R.sup.3 and R.sup.4, taken together, form a five or six-membered ring optionally containing a hetroatom selected from the group consisting of O, S, and NR.sup.1 ; wherein said five- or six-membered ring may further be substituted by one or more substituents selected from the group consisting of (CHOR.sup.1).sup.m H wherein m is 1-4, OR.sup.1, OOCR.sub.1, NR.sup.1, NCOR.sup.1 and SR.sup.1 ; Y is H, OR.sup.1, OOCR.sup.1, NR.sup.1.sub.2, NCOR.sub.1 or SR.sub.1 ; and X is --CHR.sup.5 (CHOR.sup.1).sub.2 CHR.sup.6 OR.sup.1 wherein R.sup.5 and R.sup.6 are independently H, lower alkyl (1-4C) optionally substituted with one or more R, or result in a five- or six-membered ring optionally containing a heteroatom selected from the group consisting of O, S and NR.sup.